Table 1.
Characteristics of 10,139 participants of the ACCORD study at baseline according to randomization to intensive versus standard glycemic control
| Baseline Characteristicsa | Intensive Therapy | Standard Therapy | ||
|---|---|---|---|---|
| N | Mean±SD or N (%) | N | Mean±SD or N (%) | |
| Age, yr | 5074 | 62±7 | 5065 | 62±7 |
| Women, % | 5074 | 1959 (39%) | 5065 | 1940 (38%) |
| Non-Hispanic white, % | 5074 | 3266 (64%) | 5065 | 3305 (65%) |
| Glycated hemoglobin, % | 5066 | 8.3±1.1 | 5053 | 8.3±1.1 |
| BP, mm Hg | 5050 | 5046 | ||
| Systolic | 136±17 | 137±17 | ||
| Diastolic | 75±11 | 75±11 | ||
| Cholesterol, g/dl | 5048 | 5035 | ||
| Total | 183±42 | 183±41.6 | ||
| LDL | 105±34 | 105±34 | ||
| HDL | 42±12 | 42±12 | ||
| Triglycerides | 191±148 | 190±149 | ||
| Body mass index, kg/m | 5071 | 32±6 | 5062 | 32±6 |
| Waist circumference, cm | 5019 | 107±14 | 5021 | 107±14 |
| Previous cardiovascular event, % | 5074 | 1804 (36%) | 5065 | 1755 (35%) |
| Baseline CKD status, %b | 5042 | 5022 | ||
| No CKD | 3173 (63%) | 3163 (63%) | ||
| Stage 1 | 626 (12%) | 641 (13%) | ||
| Stage 2 | 714 (14%) | 713 (14%) | ||
| Stage 3a | 425 (8%) | 419 (8%) | ||
| Stage 3b | 98 (2%) | 92 (2%) | ||
| Stage 4 | 6 (0.1%) | 0 | ||
| Baseline UACR, % | 5042 | 5022 | ||
| ≥30 μg/mg | 1247 (25%) | 1225 (24%) | ||
| ≥300 μg/mg | 226 (5%) | 241 (5%) | ||
| ≥1000 μg/mg | 97 (2%) | 99 (2%) | ||
| eGFR, ml/min per 1.73 m2b | 5074 | 83±17 | 5065 | 84±17 |
| UACR, μg/mgc | 5042 | 13.5 [6.8, 43.8] | 5022 | 13.6 [6.8, 44.4] |
| ACEI/ARB use, % | 5074 | 3428 (68%) | 5065 | 3445 (68.0%) |
| Thiazolidinedione use, % | 5074 | 986 (19%) | 5065 | 976 (19%) |
ACCORD, Action to Control Cardiovascular Risk in Diabetes; UACR, urine albumin-to-creatinine ratio; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Includes all ACCORD trial participants with at least some surveillance for primary outcome. Description of ACCORDION study population is available (43).
eGFR was calculated using the CKD Epidemiology Collaboration Creatinine Equation. Stage 1 CKD: eGFR≥90 ml/min per 1.73 m2 and UACR≥30 μg/mg; stage 2 CKD: eGFR 60–89 ml/min per 1.73 m2 and UACR≥30 μg/mg; stage 3a CKD: eGFR 45–59 ml/min per 1.73 m2; stage 3b CKD: eGFR 30–44 ml/min per 1.73 m2; stage 4 CKD: eGFR 15–29 ml/min per 1.73 m2.
Data are presented as median [IQR].